MX2018011865A - Composiciones de inmunoglobulina intravenosa recombinante (rivig) y metodos para su produccion y uso. - Google Patents
Composiciones de inmunoglobulina intravenosa recombinante (rivig) y metodos para su produccion y uso.Info
- Publication number
- MX2018011865A MX2018011865A MX2018011865A MX2018011865A MX2018011865A MX 2018011865 A MX2018011865 A MX 2018011865A MX 2018011865 A MX2018011865 A MX 2018011865A MX 2018011865 A MX2018011865 A MX 2018011865A MX 2018011865 A MX2018011865 A MX 2018011865A
- Authority
- MX
- Mexico
- Prior art keywords
- rivig
- immune
- proteins
- compositions
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 2
- 102000018358 immunoglobulin Human genes 0.000 title abstract 2
- 238000001990 intravenous administration Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 6
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 208000026278 immune system disease Diseases 0.000 abstract 3
- 241000282465 Canis Species 0.000 abstract 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 abstract 2
- 208000028622 Immune thrombocytopenia Diseases 0.000 abstract 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 abstract 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 abstract 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 abstract 2
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 abstract 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 abstract 1
- 102000009109 Fc receptors Human genes 0.000 abstract 1
- 108010087819 Fc receptors Proteins 0.000 abstract 1
- 208000003807 Graves Disease Diseases 0.000 abstract 1
- 208000015023 Graves' disease Diseases 0.000 abstract 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 abstract 1
- 208000011200 Kawasaki disease Diseases 0.000 abstract 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 abstract 1
- 206010037549 Purpura Diseases 0.000 abstract 1
- 241001672981 Purpura Species 0.000 abstract 1
- 238000010322 bone marrow transplantation Methods 0.000 abstract 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 abstract 1
- 201000001981 dermatomyositis Diseases 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010028417 myasthenia gravis Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Composiciones de proteínas de inmunoglobulina intravenosa recombinante (rIVIG) y métodos para la purificación y el uso de las proteínas Rivig; las composiciones comprenden moléculas Fc oligoméricas que se unen a los receptores de Fc con avidez elevada; las proteínas rIVIG son útiles como moléculas inmunomoduladoras para el tratamiento de trastornos inmunitarios, inclusive enfermedades autoinmunes, tales como trombocitopenia inmune refractaria, polineuropatía desmielinizante inflamatoria crónica, esclerosis múltiple, lupus, enfermedad de Graves, enfermedad de Kawasaki, dermatomiositis, miastenia gravis, síndrome de Guillain-Barre, anemia hemolítica autoinmune y otras afecciones inmunitarias e inflamatorias; las proteínas rIVIG también se pueden utilizar como inmunomoduladores en pacientes para reducir el rechazo inmunitario de trasplantes de órganos, trasplantes de células madre y trasplante de médula ósea; adicionalmente, la presente invención proporciona proteínas rIVIG de origen no humano, para su uso en trastornos inmunitarios veterinarios, tales como proteínas rIVIG caninas para el tratamiento de perros que padecen de anemia hemolítica autoinmune, púrpura trombocitopénica inmune, artritis reumatoide u otro trastorno inmunitario canino.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662315483P | 2016-03-30 | 2016-03-30 | |
| PCT/US2017/024650 WO2017172853A1 (en) | 2016-03-30 | 2017-03-29 | Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018011865A true MX2018011865A (es) | 2019-03-28 |
Family
ID=59965144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011865A MX2018011865A (es) | 2016-03-30 | 2017-03-29 | Composiciones de inmunoglobulina intravenosa recombinante (rivig) y metodos para su produccion y uso. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11304994B2 (es) |
| EP (1) | EP3436484A4 (es) |
| JP (1) | JP7075100B2 (es) |
| KR (1) | KR102477536B1 (es) |
| CN (1) | CN109312000A (es) |
| AU (1) | AU2017245143B2 (es) |
| BR (1) | BR112018070022A2 (es) |
| CA (1) | CA3019530A1 (es) |
| CL (1) | CL2018002769A1 (es) |
| CO (1) | CO2018011457A2 (es) |
| EA (1) | EA201891999A1 (es) |
| IL (1) | IL261968A (es) |
| MA (1) | MA44517A (es) |
| MX (1) | MX2018011865A (es) |
| SG (1) | SG11201808541VA (es) |
| TW (1) | TWI801336B (es) |
| WO (1) | WO2017172853A1 (es) |
| ZA (1) | ZA201806767B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3723791B1 (en) | 2017-12-14 | 2024-02-21 | CSL Behring Lengnau AG | Recombinant igg fc multimers for the treatment of neuromyelitis optica |
| WO2020077298A1 (en) * | 2018-10-11 | 2020-04-16 | Momenta Pharmaceuticals, Inc. | Treatment with highly silylated igg compositions |
| KR20210110563A (ko) * | 2018-10-18 | 2021-09-08 | 킨드레드 바이오사이언시스, 인코포레이티드 | 수의학적 용도를 위한 신생아 fc 수용체(fcrn)에 변경된 결합을 갖는 fc 변이체 |
| CN109793894A (zh) * | 2019-04-03 | 2019-05-24 | 长春西诺生物科技有限公司 | 犬免疫球蛋白在制备犬溶血性贫血药物中的应用 |
| KR20220062084A (ko) | 2019-09-13 | 2022-05-13 | 체에스엘 베링 렝나우 아게 | 면역 복합체 매개된 콩팥 장애의 치료를 위한 재조합 IgG Fc 다량체 |
| CN112899301B (zh) * | 2021-01-29 | 2023-04-11 | 中国热带农业科学院热带生物技术研究所 | 一种木薯普通花叶病毒诱导的基因沉默***及其应用 |
| CN117964777A (zh) * | 2021-08-26 | 2024-05-03 | 瑅安生物医药（杭州）有限公司 | 一种接近天然分子的多肽融合分子 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100497849B1 (ko) * | 1997-08-21 | 2005-06-29 | 다카라 바이오 가부시키가이샤 | 제암제 |
| DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| GB0015426D0 (en) | 2000-06-24 | 2000-08-16 | Univ Southampton | Method for generating soluble highly multimeric proteins |
| WO2002072608A2 (en) | 2001-03-09 | 2002-09-19 | University Of Chicago | POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS |
| US7279329B2 (en) * | 2005-10-17 | 2007-10-09 | Industrial Technology Research Institute | Expression system for producing collagen |
| US20070264687A1 (en) | 2005-12-15 | 2007-11-15 | Min-Yuan Chou | Recombinant triplex scaffold-based polypeptides |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| CA2682605A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| BRPI0811857A2 (pt) * | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
| ES2565834T3 (es) | 2007-06-01 | 2016-04-07 | University Of Maryland, Baltimore | Agentes de unión a receptor de Fc de región constante de inmunoglobulina |
| WO2010065578A2 (en) | 2008-12-04 | 2010-06-10 | Leukosight Inc. | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME |
| MX368531B (es) * | 2010-07-28 | 2019-10-07 | Gliknik Inc | Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente. |
| EP2561888A1 (en) | 2011-08-23 | 2013-02-27 | Deutsches Krebsforschungszentrum | Protein comprising NC-1 for treating angiogenesis-related diseases |
| TWI476001B (zh) | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Ｆｃ融合蛋白及其用途 |
| US9962436B2 (en) * | 2012-07-26 | 2018-05-08 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Multimeric fusion protein vaccine and immunotherapeutic |
| EP2885320A4 (en) | 2012-08-20 | 2016-04-06 | Gliknik Inc | MOLECULES WITH ANTIGEN-BINDING AND POLYVALENT FC GAMMA RECEPTOR BINDING ACTIVITY |
| US20150218236A1 (en) * | 2012-10-17 | 2015-08-06 | Liverpool School Of Tropical Medicine | Immunomodulatory proteins |
| PT2968461T (pt) | 2013-03-13 | 2022-12-26 | Genzyme Corp | Proteínas de fusão que compreendem porções de ligação ao pdgf e ao vegf e seus métodos de utilização |
| US20150038682A1 (en) | 2013-08-02 | 2015-02-05 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via homomultimerizing peptide |
| WO2015158867A1 (en) | 2014-04-16 | 2015-10-22 | Ucb Biopharma Sprl | Multimeric fc proteins |
| WO2017024114A1 (en) | 2015-08-06 | 2017-02-09 | President And Fellows Of Harvard College | Improved microbe-binding molecules and uses thereof |
-
2017
- 2017-03-29 CA CA3019530A patent/CA3019530A1/en active Pending
- 2017-03-29 JP JP2019503393A patent/JP7075100B2/ja active Active
- 2017-03-29 CN CN201780033114.8A patent/CN109312000A/zh active Pending
- 2017-03-29 BR BR112018070022A patent/BR112018070022A2/pt unknown
- 2017-03-29 US US16/089,042 patent/US11304994B2/en active Active
- 2017-03-29 EA EA201891999A patent/EA201891999A1/ru unknown
- 2017-03-29 MA MA044517A patent/MA44517A/fr unknown
- 2017-03-29 MX MX2018011865A patent/MX2018011865A/es unknown
- 2017-03-29 SG SG11201808541VA patent/SG11201808541VA/en unknown
- 2017-03-29 KR KR1020187030960A patent/KR102477536B1/ko active IP Right Grant
- 2017-03-29 EP EP17776516.1A patent/EP3436484A4/en active Pending
- 2017-03-29 AU AU2017245143A patent/AU2017245143B2/en active Active
- 2017-03-29 WO PCT/US2017/024650 patent/WO2017172853A1/en active Application Filing
- 2017-03-30 TW TW106110897A patent/TWI801336B/zh active
-
2018
- 2018-09-26 IL IL261968A patent/IL261968A/en unknown
- 2018-09-28 CL CL2018002769A patent/CL2018002769A1/es unknown
- 2018-10-11 ZA ZA2018/06767A patent/ZA201806767B/en unknown
- 2018-10-26 CO CONC2018/0011457A patent/CO2018011457A2/es unknown
-
2022
- 2022-03-29 US US17/707,243 patent/US11801286B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201806767B (en) | 2023-04-26 |
| EA201891999A1 (ru) | 2019-08-30 |
| BR112018070022A2 (pt) | 2019-02-05 |
| US20220233658A1 (en) | 2022-07-28 |
| WO2017172853A1 (en) | 2017-10-05 |
| US20190111115A1 (en) | 2019-04-18 |
| SG11201808541VA (en) | 2018-10-30 |
| TWI801336B (zh) | 2023-05-11 |
| CA3019530A1 (en) | 2017-10-05 |
| US11801286B2 (en) | 2023-10-31 |
| CL2018002769A1 (es) | 2018-12-28 |
| IL261968A (en) | 2018-10-31 |
| JP7075100B2 (ja) | 2022-05-25 |
| JP2019513024A (ja) | 2019-05-23 |
| AU2017245143B2 (en) | 2024-01-11 |
| TW201741335A (zh) | 2017-12-01 |
| US11304994B2 (en) | 2022-04-19 |
| EP3436484A1 (en) | 2019-02-06 |
| KR102477536B1 (ko) | 2022-12-13 |
| CO2018011457A2 (es) | 2019-02-08 |
| EP3436484A4 (en) | 2019-12-04 |
| KR20180132731A (ko) | 2018-12-12 |
| MA44517A (fr) | 2019-02-06 |
| AU2017245143A1 (en) | 2018-10-18 |
| CN109312000A (zh) | 2019-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018011865A (es) | Composiciones de inmunoglobulina intravenosa recombinante (rivig) y metodos para su produccion y uso. | |
| NZ741404A (en) | Anti-il-2 antibodies and compositions and uses thereof | |
| MX2019014695A (es) | Proteinas de fusion de interleucina-2 y usos de las mismas. | |
| PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
| GB201112429D0 (en) | Antigen-binding proteins with increased FcRn binding | |
| EA202191380A1 (ru) | Антитела к альфа-синуклеину и их применение | |
| PH12016500242A1 (en) | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof | |
| EA201892619A1 (ru) | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 | |
| SG10201909806SA (en) | Production of t cell retargeting hetero-dimeric immunoglobulins | |
| EA201890655A1 (ru) | Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул | |
| MX2018002068A (es) | Purificacion de fkpa y usos de la misma para producir polipeptidos recombinantes. | |
| TW200716674A (en) | Anti-GM-CSF antibodies and uses therefor | |
| PH12017501522A1 (en) | Antibodies to tau and uses thereof | |
| EA201290973A1 (ru) | Соединения и способы модулирования киназ и показания по их применению | |
| MX2016012479A (es) | Miembros de unión al factor de necrosis tumoral (tnf) alfa. | |
| TN2018000159A1 (en) | Improved tnf binders. | |
| CL2016001028A1 (es) | Anticuerpos de alta afinidad y de agregación estable basados en dominios variables de vl y derivados de vhh. | |
| MX2020007628A (es) | Composiciones y metodos de uso. | |
| EA201691521A1 (ru) | Антитела к интерлейкину-21 | |
| EA202190807A1 (ru) | Антитела к синуклеину | |
| GB2543713A (en) | Polymeric proteins and uses thereof | |
| EA201790437A1 (ru) | Антигенсвязывающие белки, связывающиеся с cxcr3 | |
| NZ724772A (en) | Antibodies against hpa-1a | |
| JOP20200106A1 (ar) | جسم مضاد أحادي النسيلة مضاد لـ il-5r? | |
| MX2016002188A (es) | Composición farmacéutica de proteínas híbridas recombinantes capaces de generar anticuerpos neutralizantes en contra del veneno de alacranes. |